Novavax Inc. Reports Strong Q3 2026 Results and Raises Full‑Year Revenue Guidance

Novavax Inc. (Nasdaq: NVAX), a clinical‑stage biotechnology company focused on vaccine development, announced its third‑quarter 2026 financial results on November 5, 2026. The company reported total revenue of $68 million, a 3.5 % decline from the previous quarter but still above the FactSet consensus of $50 million.

Earnings and Guidance

  • Adjusted earnings per share: $‑0.19, an improvement over the consensus estimate of $‑0.35.
  • Full‑year 2026 non‑GAAP adjusted total revenue: The company now projects $385 – 415 million, up from the prior range of $235 – 275 million. The midpoint of the revised guidance is $400 million.
  • Revenue from Nuvaxovid: Projected to be $40 – 50 million, compared with $35 – 45 million previously.
  • Adjusted delivery revenue: Expected to reach $50 – 60 million, versus $45 – 55 million earlier.

The company attributes the upside to a $125 million milestone payment received from Sanofi following the launch of a Phase 3 influenza‑COVID‑19 combination vaccine trial in Europe. Sanofi has also confirmed plans to initiate a U.S. Phase 3 trial in 2027.

Operational Highlights

Novavax’s strategy remains structured around three pillars:

  1. Vaccines for infectious diseases – The company continues to advance its differentiated C. difficile vaccine program, which is anticipated to enter clinical development by 2027.
  2. Broad‑based vaccine platform – Multiple experiments using Matrix‑M® adjuvant are underway across a spectrum of infectious disease targets and oncology models.
  3. Financial sustainability – The updated revenue framework projects a cash runway through 2029, providing a buffer for continued R&D investment.

The company also reported a modest improvement in GAAP combined R&D and SG&A expense guidance, reduced by $5 million at the midpoint.

Market Reaction

Despite the earnings and sales beat, NVAX shares fell 8 % in early trading on November 6, 2026. Analysts noted that the decline may reflect concerns over the company’s negative price‑earnings ratio of ‑7.01 and the broader market volatility affecting biotech stocks. The stock closed at $9.78 on November 4, 2026, after having reached a 52‑week high of $13.39 on October 4 and a 52‑week low of $6.20 on November 19, 2025.

Outlook

With the new revenue guidance and the anticipated launch of additional vaccine candidates, Novavax aims to strengthen its pipeline while maintaining a sustainable cash position through 2029. The company will host a conference call at 8:30 a.m. ET on November 5, 2026, to discuss the results in detail.